Styris Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.90 M
as on 04-07-2024
- Paid Up Capital ₹ 0.90 M
as on 04-07-2024
- Company Age 24 Year, 8 Months
- Last Filing with ROC 31 Mar 2021
- Satisfied Charges ₹ 2.13 M
as on 04-07-2024
- Revenue -7.81%
(FY 2020)
- Profit -11.95%
(FY 2020)
- Ebitda 12.88%
(FY 2020)
- Net Worth 7.38%
(FY 2020)
- Total Assets -9.71%
(FY 2020)
About Styris Pharma
The Corporate was formerly known as Lorven Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.90 M and a paid-up capital of Rs 0.90 M.
The company has closed loans amounting to ₹2.13 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Kodanda Pilla and Venkata Pilla serve as directors at the Company.
- CIN/LLPIN
U24239TG2000PTC034175
- Company No.
034175
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Apr 2000
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Styris Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kodanda Pilla  | Managing Director | 03-Apr-2000 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Venkata Pilla | Director | 11-Feb-2013 | Current |
Financial Performance of Styris Pharma.
Styris Pharma Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 7.81% decrease. The company also saw a substantial fall in profitability, with a 11.95% decrease in profit. The company's net worth moved up by a moderate rise of 7.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Styris Pharma?
In 2018, Styris Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Stywel Life Sciences Private LimitedActive 3 years 9 monthsKodanda Pilla and Venkata Pilla are mutual person
- Maxwin Marketing Private LimitedActive 24 years 2 months
Kodanda Pilla and Venkata Pilla are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
City Union Bank Limited Creation Date: 21 Feb 2008 | ₹2.00 M | Satisfied |
Sri Lakshmi Vilas Bank Ltd. Creation Date: 28 Feb 2006 | ₹0.13 M | Satisfied |
How Many Employees Work at Styris Pharma?
Unlock and access historical data on people associated with Styris Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Styris Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Styris Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
